表皮生长因子受体酪氨酸激酶抑制剂耐药后非小细胞肺癌治疗研究进展

表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinease inhibitors ，EGFR-TKIs）对EGFR 敏感突变非小细胞肺癌（non small cell lung cancer，NSCLC ）除了其卓越的疗效，也如其他药物一样最终不可避免地发生耐药。EGFR 基因突变是最常见的肺癌驱动基因之一，针对 EGFR-TKI 耐药后的处理，目前虽无固定治疗模式，但临床进行了大量的探索性研究及治疗对策的探讨，部分结果对临床治疗这类患者有一定启示。本文将就近年具有代表性的研究及进展做一论述。

Treatment after acquired resistance to EGFR-TKI of non-small cell lung cancer

Epidermal growth factor receptor tyrosine- kinase inhibitors (EGFR- TKIs) have elicited curative effects on patients with advanced non- small cell lung cancer and with activating mutations in the EGFR gene. However, acquired resistance to EGFR-TKIs is eventually developed after an initial response is induced; as such, patients with acquired resistance must be treated with more ef-fective strategies to delay or possibly overcome the resistance. This article reviews available data on the treatment of patients who have failed to respond to EGFR-TKI.